One Equity Partners, the global private investment arm of J.P. Morgan Chase & Co., announced March 10 it completed the acquisition of PeroxyChem, formerly FMC Global Peroxygens. The acquisition includes all sales, manufacturing, supply chain and R&D capabilities of FMC Global Peroxygens.
The purchase was valued at approximately $200 million.
This acquisition enables PeroxyChem to extend its market position in the manufacturing of hydrogen peroxide, persulfates, peracetic acid and environmental remediation technologies, according to the company. PeroxyChem expects no changes to daily operations as a result of the sale.
For more information, visit www.peroxychem.com.